Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

New Roche hemophilia drug prevents bleeds

The investigational hemophilia drug emicizumab cut the bleed rate by 87% in patients with resistance to standard therapy versus those receiving another treatment.

Read More »

Investors Relieved as Seattle Genetics Pulls Out Win for Phase III Lymphoma Trial

Seattle Genetics and Takeda Pharmaceutical Company announced positive results from the Phase III ECHELON-1 clinical trial in previously untreated advanced classical Hodgkin lymphoma.

Read More »

EU regulators greenlight U.S. biotech Aveo’s kidney cancer drug

European regulators recommended the approval of Aveo Pharmaceuticals Inc.’s drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market.

Read More »

EU backs second biosimilar copy of Humira

European regulators recommended approval of a second copy of AbbVie’s rheumatoid arthritis drug Humira, the world’s top-selling medicine.

Read More »

Germany’s Merck gets EU backing for oral MS drug

Merck KGaA won a key recommendation to become an entrant to the oral MS drug market in Europe, six years after its first attempt to launch the cladribine pill failed.

Read More »

Novartis breast cancer drug Kisqali wins European panel backing

A European Medicines Agency (EMA) panel recommended approving Novartis’s Kisqali drug, bolstering the Swiss drugmaker’s bid to challenge rival Pfizer’s Ibrance against tough-to-treat breast cancer.

Read More »

FDA Calls Cara Therapeutics’ Kidney Disease Drug a Breakthrough, Stock Soars

Shares of pain-relief company Cara Therapeutics were up more than 16 percent after the company grabbed the Breakthrough Therapy Designation for its chronic kidney disease treatment CR845.

Read More »

bluebird bio Touts Impressive Data From Late-Stage Gene Therapy Study

bluebird bio’s interim data for its Phase III gene therapy LentiGlobin trial showed promising results in reducing a patient’s need for blood transfusions after one month after treatment, but the data also raised some concerns.

Read More »

FDA Approves Rituxan Hycela for Subcutaneous Injection in Certain Blood Cancers

The U.S. FDA approved Genentech’s Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with certain blood cancers.

Read More »

Mylan shareholders vote against executive pay, re-elect board

Mylan NV shareholders voted against the generic drugmaker’s executive pay policy but re-elected the board at its 2017 annual meeting despite a shareholder campaign in the wake of a scandal over high prices for its EpiPen emergency allergy treatment.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom